{
    "2021-09-08": [
        [
            {
                "time": "",
                "original_text": "大摩：上调复星医药(2196.HK)目标价至61.3港元 评级“与大市同步”",
                "features": {
                    "keywords": [
                        "复星医药",
                        "目标价",
                        "上调",
                        "61.3港元",
                        "与大市同步"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "大摩：予复星医药(02196)“与大市同步”评级 目标价升9.4%至61.3港元",
                "features": {
                    "keywords": [
                        "复星医药",
                        "目标价",
                        "上升",
                        "9.4%",
                        "61.3港元",
                        "与大市同步"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}